Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

President Donald Trump said Wednesday that he is directing the opening of a detention center at Guantanamo Bay to hold up to ...

Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.

Eisai and Biogen have reported data showing that a subcutaneous formulation of its Alzheimer’s disease therapy Leqembi matched the current intravenous version at clearing amyloid deposits in the ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Whether you're curious to explore a healthy brain or brains affected by Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, or Frontotemporal dementia, the choice is yours. Tailoring ...